The Company is also developing MaxDerm, a Ceplene-related series of drug candidates for the treatment of certain topical disorders. Furthermore, through its proprietary high-throughput screening technology, the Company has identified compounds that may serve as inhibitors and activators of caspases, key enzymes that modulate and carry out the cellular signaling pathways involved in programmed cell death, also known as apoptosis. Net loss applicable to Com.
Revenues reflect the licensing of anti-cancer compounds.
Higher loss suffered from increased information systems costs. Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Event data provided by StreetEvents .